Skip to content
Open access

Pneumonitis Associated with Immune Checkpoint Inhibitors and Targeted Anticancer Therapies: A Retrospective Case Series of 12 Patients

Aug 2026 · Diseases · Vol 14, pp. 313 · 0 citations · 36 references
Medicine

TL;DR

Pneumonitis improved or resolved in 11 of the 12 patients; one patient deteriorated after reintroduction of immunotherapy and subsequently died from cancer-related complications, and extensive tests may be reserved for non-responsive cases.

Abstract

Background: Immunotherapy and targeted therapy have gained ground over conventional chemotherapy in treating various cancers. While pulmonary toxicity associated with these agents is rare, it represents a significant factor in both mortality and morbidity and may influence the overall success of cancer treatment. This case series report adds to the emerging evidence of cancer therapy-induced pneumonitis features and corticotherapy outcomes. Patients and methods: This single-center, retrospective case series analyzed 12 consecutive cases of patients undergoing immunotherapy (four receiving nivolumab, four receiving pembrolizumab) or targeted therapy (three receiving obinutuzumab, one receiving abemaciclib) for cancer (seven with lung cancer, three with non-Hodgkin lymphoma, one with breast cancer, one with renal cancer) who developed pneumonitis during their follow-up. Results: The interval from oncological treatment initiation to pneumonitis onset ranged from 6 to 48 months (median = 18.5), and in four patients it occurred after discontinuation of oncologic therapy. In most patients, the diagnosis was established with high probability based only on the clinical presentation, radiologic pattern, and concomitant oncologic therapy. Bronchoscopy with bronchoalveolar lavage analysis was performed in eight of the 12 patients, particularly when onset followed treatment discontinuation. The main symptom was dyspnea (10/12 cases), and three of 12 patients had respiratory failure (SpO2 ≤ 88%). The CTCAE severity grades were: one mild, seven moderate, three severe, and one life-threatening. The CT scan showed different patterns (7 OP, 4 NSIP-like, and 1 HP). Eleven patients received oral methylprednisolone (0.40 to 0.82 mg/kg) for 5 to 16 weeks. Two patients continued oncologic treatment, and six discontinued. Pneumonitis improved or resolved in 11 of the 12 patients; one patient deteriorated after reintroduction of immunotherapy and subsequently died from cancer-related complications. Conclusions: Immunotherapy- and targeted therapy-induced pneumonitis can express various features and severities, and prompt recognition and diagnosis based on clinical, radiologic and contextual elements are mandatory. In this small, heterogeneous series the individualized corticosteroid regimens used were followed by favorable outcomes. Our observations suggest that, in selected clinically improving patients, follow-up may rely only on clinical assessment and chest X-ray, and extensive tests may be reserved for non-responsive cases.

Read PDF

Similar papers

Sep 2026

Risk Factors for Pneumonitis Induced by Combined Radiotherapy and Immunotherapy: A Multicenter Prospective Study.

BACKGROUND The combination of radiotherapy (RT) and immune checkpoint inhibitors (ICIs) has become an important therapeutic approach for lung cancer. However, pneumonitis remains a major treatment-related toxicity of this therapeutic approach, and the risk factors for pneumonitis associated with combined RT and ICIs un...

Ling-Yan Xiao, Qian Li, Ying Li et al. · 0 citations
Review Open access Sep 2026

Induction immunochemotherapy followed by definitive radiotherapy for inoperable NSCLC: A retrospectivecohort study.

The treatment approach of induction ICIs combined with chemotherapy followed by definitive radiotherapy, with or without consolidation immunotherapy, has shown encouraging efficacy and is safe to administer, but further research is still needed to confirm these findings.

Jiu-Yang Chen, Nan-Xi Li, Xi Yang et al. · 0 citations
Review Open access Oct 2026

Immune Checkpoint Inhibitor-Associated Pneumonitis in Patients Treated for Metastatic Renal Cell Carcinoma

Simple Summary Immunotherapy has improved outcomes for many people with metastatic kidney cancer, but it can cause inflammation of the lungs, known as pneumonitis. This complication can be difficult to distinguish from infection, cancer progression, or prior radiation-related lung injury and can sometimes be life-threa...

Jack Masur, Abhishek Mullapudi, Soham Ali et al. · 0 citations
Open access Sep 2026

Immunotherapy and Targeted Therapy for Metastatic Renal Cell Carcinoma

Lenvatinib plus pembrolizumab provides significant improvements in PFS and objective response compared with sunitinib, while nivolumab plus ipilimumab demonstrates durable long-term survival benefits.

Zhumagazin Zhanabay Derbesinovich · 0 citations
Open access Aug 2026

Toripalimab combined with chemotherapy in the treatment of primary tracheal squamous cell carcinoma: a phase II proof-of-concept study

Background Despite immunotherapy advancements for many solid cancers, role of first-line immunotherapy for tracheal malignancies is uncertain. This study aimed to evaluate the efficacy and safety of toripalimab with chemotherapy for initially-unresectable locally-advanced tracheal squamous cell carcinoma (SCC). Methods...

Jie Dai, Xin-Yun Fang, Xin-Sheng Zhu et al. · 0 citations
Review Open access Oct 2026

Acute myeloid leukemia following icotinib therapy for non-small cell lung cancer: a case report and literature review

Icotinib significantly improves survival and prognosis in patients with epidermal growth factor receptor (EGFR)-sensitive non-small cell lung cancer (NSCLC). It is generally well-tolerated, with treatment-related myeloid neoplasm (t-MN) being a rare adverse reaction. We report a case of a 75-year-old female patient wit...

Hui-Ling Huang, Lui Song, Fang-Qin Tong et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.